Pre-prints

Dual Targeting of FLT3 and LSD1 Disrupts the MYC Super-Enhancer Complex in Acute Myeloid Leukemia
Yashar W*, Smith BM*, Coleman DJ, VanCampen J, Kong G, Macaraeg J, Estabrook J, Demir E, Long N, Bottomly D, McWeeney SK, Tyner JW, Druker BJ, Maxson JE, Braun TP. bioRxiv. 2022.

ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II
​Braun TP, Estabrook, Coleman DJ, Schonrock Z, Smith BM, Enright T, Coblentz C, Callahan R, Mohammed H, Druker BJ, Lusardi TA, Maxson JE. bioRxiv. 2021.

Publications

GoPeaks: histone modification peak calling for CUT&Tag
Yashar WY*, Kong G*, VanCampen J*, Curtiss BM*, Coleman DJ, Carbone L, Yardimci GG, Braun TP. BMC Genome Biology. 2022.

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia
Smith BM, VanCampen J, Kong GL, Yashar W, Tsang YH, Horton W, Coleman DJ, Estabrook J, Lusardi TA, Mills GB, Druker BJ, Maxson JE, Braun TP. Leukemia. 2022.

Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia
​Braun TP, Coblentz C, Smith BM, Coleman DJ, Schonrock Z, Carratt SA, Callahan RL, Maniaci B, Druker BJ, Maxson JE. PNAS. 2020.

Response and Resistance to BCR-ABL1 Targeted Therapies
​Braun TP, Eide CA, Druker BJ. Cancer Cell. 2020

Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia
Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, Watanabe-Smith K, , Jeng S, Smith JL, Leonti AR, Ries RE, McWeeney S, Genua CD, Drissen R, Nerlov C, Meshinchi S, Carbone L, Druker BJ, Maxson JE. Nature Communications. 2019.

​Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
Braun TP, Maxson JE, Agarwal A, Dunlap J, Spurgeon SE, Traer E. Leuk Res Rep. 2014​.
​